



Mereo BioPharma plc
Support for Healthcare Professionals 2019

Location	Consultant	Description of Services	Programme	Amount (£)
USA	Gerard Criner	Attendance at FDA Type B Regulatory Meeting	Acumapimod (BCT197)	1,953
UK	Nick Bishop	General support and consultancy for the Setrusumab programme	Setrusumab (BPS-804)	2,634
UK	Kassim Javaid	General support and consultancy for the Setrusumab programme	Setrusumab (BPS-804)	250
UK	Richard Eastell	Attendance of the Setrusumab Advisory Board and review of BGS-649 bone data	Setrusumab (BPS-804) / Leflutrozole (BGS649)	2,310
USA	Adrian Dobbs	Attendance of the Leflutrozole Advisory Board	Leflutrozole (BGS649)	5,325
Latvia	Ugis Gruntmanis	Attendance of the Leflutrozole Advisory Board	Leflutrozole (BGS649)	2,243
Germany	Oliver Semler	Attendance of the Setrusumab Advisory Board & Attendance at European Medicines Agency Scientific Advice for biomarker qualification	Setrusumab (BPS804)	3,090
UK	Thomas Hugh Jones	Attendance of the Leflutrozole Advisory Board	Leflutrozole (BGS649)	2,100
Canada	Francis Glorieux	General support and consultancy for the BPS programme	Setrusumab (BPS804)	653
Italy	Mario Maggi	Attendance of the Leflutrozole Advisory Board	Leflutrozole (BGS649)	2,113
UK	Allan Pacey	Attendance of the Leflutrozole Advisory Board	Leflutrozole (BGS649)	1,680
USA	Vernon Reid Sutton	Attendance of the Setrusumab Advisory Board	Setrusumab (BPS804)	2,276
USA	Cathleen Raggio	Attendance of the Setrusumab Advisory Board	Setrusumab (BPS804)	2,165
Canada	Frank Rauch	Attendance of the Setrusumab Advisory Board	Setrusumab (BPS804)	2,856